Search Result

Isoforms Recommended:	CCR2

Results for "

ccr2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (65) Bacterial (1) CXCR (1) Drug Isomer (2) E1/E2/E3 Enzyme (1) HIV (4) Ligands for Target Protein for PROTAC (1) mRNA (1) PROTACs (2) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (4) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (10) Cardiovascular Disease (2) Endocrinology (27) Infection (6) Inflammation/Immunology (41) Metabolic Disease (6) Neurological Disease (4)
Oligonucleotides:	Nucleotide Analogs (1) Chemokine & Receptors (1) Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: CCR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15418

RS 504393 Maximum Cited Publications 30 Publications Verification	CCR	Inflammation/Immunology Endocrinology
RS 504393 is a selective *CCR2* chemokine receptor antagonist (IC₅₀ values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).

HY-14882

Cenicriviroc 5+ Cited Publications TAK-652; TBR-652	CCR HIV	Infection Endocrinology
Cenicriviroc (TAK-652) is an orally active, dual *CCR2/CCR5* antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity .

HY-50674

INCB3344 Maximum Cited Publications 30 Publications Verification	CCR	Inflammation/Immunology Endocrinology
INCB3344 is a potent, selective and orally bioavailable *CCR2* antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-18611A

Abaucin 20+ Cited Publications RS102895; MLJS-21001	CCR	Neurological Disease Endocrinology
RS102895 is a potent *CCR2* antagonist, with an IC₅₀ of 360 nM, and shows no effect on CCR1.

HY-12080

BX471 20+ Cited Publications ZK-811752	CCR	Inflammation/Immunology Endocrinology
BX471 (ZK-811752) is an orally active, potent and selective non-peptide *CCR1* antagonist with a K_i of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

HY-109593

BMS-813160 1 Publications Verification	CCR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
BMS-813160 is a potent and selective *CCR2/5* dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC₅₀s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation ^[2].

HY-50669

MK-0812 1 Publications Verification	CCR	Inflammation/Immunology Endocrinology
MK-0812 is a potent and selective *CCR2* antagonist with low nM affinity for CCR2.

HY-13245

PF-4136309 5 Publications Verification INCB8761	CCR	Inflammation/Immunology Endocrinology
PF-4136309 is a potent, selective, and orally bioavailable *CCR2* antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-101908

*BMS CCR2* 22** 1 Publications Verification	CCR	Inflammation/Immunology Endocrinology
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC₅₀ of 5.1 nM) and potent functional antagonism (calcium flux IC₅₀ of 18 nM and chemotaxis IC₅₀ of 1 nM) ^[2].

HY-108323

CCR2 antagonist 4 5+ Cited Publications Teijin compound 1	CCR	Inflammation/Immunology
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific *CCR2* antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-103362

CCR2 antagonist 4 hydrochloride 5+ Cited Publications Teijin compound 1 hydrochloride	CCR	Inflammation/Immunology
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific *CCR2* antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-14882A

Cenicriviroc Mesylate 5+ Cited Publications TAK-652 Mesylate; TBR-652 Mesylate	CCR HIV	Infection Inflammation/Immunology Endocrinology
Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual *CCR2/CCR5* antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

HY-12080A

BX471 hydrochloride 20+ Cited Publications ZK-811752 hydrochloride	CCR	Inflammation/Immunology Endocrinology
BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide *CCR1* antagonist with K_i of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

HY-P99781

Plozalizumab MLN-1202	CCR	Inflammation/Immunology Cancer
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) ^[2] .

HY-101713

Ilacirnon 1 Publications Verification CCX140; CCX140-B	CCR	Metabolic Disease Endocrinology
CCX140 (CCX140-B) is a potent *CCR2* antagonist.

HY-18611

Abaucin hydrochloride 20+ Cited Publications RS102895 hydrochloride; MLJS-21001 hydrochloride	CCR	Neurological Disease Endocrinology
RS102895 hydrochloride is a potent *CCR2* antagonist, with an IC₅₀ of 360 nM, and shows no effect on CCR1.

HY-50669A

MK-0812 Succinate 1 Publications Verification	CCR	Inflammation/Immunology Endocrinology
MK-0812 Succinate is a potent and selective *CCR2* antagonist with high affinity at CCR2.

HY-13499

JNJ-41443532 ccr2 antagonist 5	CCR	Inflammation/Immunology
JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active *hCCR2* inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .

HY-101264

CCR2 antagonist 3	CCR	Inflammation/Immunology Endocrinology
CCR2 antagonist 3 is a chemokine receptor 2 *(CCR2)* antagonist.

HY-135891

AZD2423	CCR	Neurological Disease
AZD2423 is a potent, selective, orally bioavailable, and non-competitive *CCR2* chemokine receptor negative allosteric modulator. AZD2423 has an IC₅₀ of 1.2 nM for CCR2 Ca ²⁺ flux ^[2] .

HY-50081

CCR2-RA-[R] 4 Publications Verification	CCR	Inflammation/Immunology Endocrinology
CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC₅₀ of 103 nM.

HY-103360

J-113863 3 Publications Verification	CCR	Inflammation/Immunology
J-113863 is a potent and selective *CCR1* antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse *CCR1* receptors, respectively. J-113863 is also a potent antagonist of the human *CCR3* (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse *CCR3* (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect ^[2] .

HY-19974

TAK-220 3 Publications Verification	CCR HIV	Infection Endocrinology
TAK-220 is a selective and orally bioavailable *CCR5* antagonist, with IC₅₀s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC₅₀s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC₉₀s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.

HY-112792

CCR2 antagonist 1 1 Publications Verification	CCR	Endocrinology
CCR2 antagonist 1 (compound 15a) is a high-affinity and long-residence-time *CCR2* antagonist, with a K_i of 2.4 nM .

HY-110132

JNJ-27141491	CCR	Inflammation/Immunology
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human *CCR2* .

HY-117621

PF-04634817	CCR	Metabolic Disease
PF-0463481 is a potent and orally active dual *CCR2/CCR5* antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-117621A

PF-04634817 succinate	CCR	Metabolic Disease
PF-0463481 succinate is a potent and orally active dual *CCR2/CCR5* antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-15450A

INCB 3284 2 Publications Verification	CCR	Endocrinology
INCB 3284 is a potent, selective and orally bioavailable human *CCR2* antagonist, inhibiting monocyte chemoattractant protein-1 binding to *hCCR2, with an IC₅₀* of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.

HY-112874

BMS-681 BMS-687681	CCR	Neurological Disease Inflammation/Immunology Cancer
BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer .

HY-RS02151

CCR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CCR	Others
CCR2 Human Pre-designed siRNA Set A contains three designed siRNAs for CCR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CCR2 Human Pre-designed siRNA Set A CCR2 Human Pre-designed siRNA Set A

HY-174746

*Human CCR2* mRNA**	mRNA	Inflammation/Immunology
Human CCR2 mRNA encodes the human C-C motif chemokine receptor 2 (CCR2) protein, a chemokine which specifically mediates monocyte chemotaxis. CCR2 can mediate agonist-dependent calcium mobilization and inhibition of adenylyl cyclase.

HY-RS02152

Ccr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CCR	Others
Ccr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ccr2 Mouse Pre-designed siRNA Set A Ccr2 Mouse Pre-designed siRNA Set A

HY-RS02153

Ccr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CCR	Others
Ccr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ccr2 Rat Pre-designed siRNA Set A Ccr2 Rat Pre-designed siRNA Set A

HY-180572

CCR2 ligand-1	Ligands for Target Protein for PROTAC CCR	Cancer
CCR2 ligand-1 is a ligand for *CCR2. CCR2* ligand-1 conjugates with the Linker PIN1 degrader-3 (HY-79577) and the E3 ligase ligand Thalidomide 4-fluoride (HY-41547) can be used for the synthesis of LUF7996 (HY-180571) .

HY-77111

cis-INCB3344 1 Publications Verification	CCR Drug Isomer	Inflammation/Immunology Endocrinology
cis-INCB3344 is the isomer of INCB3344 (HY-50674), and can be used as an experimental control. INCB3344 is a potent, selective and orally bioavailable *CCR2* antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-108432

BMS-741672	CCR	Inflammation/Immunology
BMS-741672 is a selective and orally active *CCR2* antagonist with an IC₅₀ of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5 .

HY-100819

RO5234444	CCR	Metabolic Disease
RO5234444 is an orally active *CCR2* antagonist, with IC₅₀s of 22nM for human *CCR2* and 161 nM for mouse *CCR2*. RO5234444 alleviates glomerulosclerosis, reduces albuminuria, and significantly improves the glomerular filtration rate (GFR) in the uninephrectomized (1K) type 2 diabetic db/db mouse model. RO5234444 can be used for the study of type 2 diabetic nephropathy .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective *CCR2* inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-185299

CCR2 antagonist 6	CCR	Inflammation/Immunology
CCR2 antagonist 6 (Example 98) is a *CCR2* antagonist (K_b: 0.215 μM for CCR2, 0.174 μM for hCCR2B). CCR2 antagonist 6 can be used in the research of inflammation and autoimmune diseases .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective *CCR2* inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-101908R

*BMS CCR2* 22 (Standard)**	Reference Standards CCR	Inflammation/Immunology Endocrinology
BMS CCR2 22 (Standard) is the analytical standard of BMS CCR2 22 (HY-101908). This product is intended for research and analytical applications. BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC₅₀ of 5.1 nM) and potent functional antagonism (calcium flux IC₅₀ of 18 nM and chemotaxis IC₅₀ of 1 nM) ^[2].

HY-177596

Dicytidine 5′-triphosphate Cp3C	CCR	Others
Dicytidine 5′-triphosphate (Cp3C) is a cytosine-containing dinucleoside polyphosphate. Dicytidine 5′-triphosphate inhibits the intracellular accumulation of trans-resveratrol and trans-piceid. Dicytidine 5′-triphosphate induces the expression of *CCR2* and upregulates the expression of PAL1 and 4CL1 .

HY-15418R

RS 504393 (Standard)	CCR	Inflammation/Immunology Endocrinology
RS 504393 (Standard) is the analytical standard of RS 504393. This product is intended for research and analytical applications. RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).

HY-136768

YJC-10592	CCR	Inflammation/Immunology
YJC-10592 is an orally active *CCR-2* antagonist. YJC-10592 binds to HAS. YJC-10592 can be used in the research of asthma and idiopathic dermatitis .

HY-P991745

*Anti-Mouse CCR2* Antibody (C2Mab-6)**	CCR	Inflammation/Immunology
Anti-Mouse CCR2 Antibody (C2Mab-6) is raised against and binds to the N-terminal sequence of *CCR2*. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979) .

HY-112792A

*(1S)-CCR2* antagonist 1**	CCR	Endocrinology
(1S)-CCR2 antagonist 1 is a left-handed chiral body of CCR2 antagonist 1 (HY-112792). CCR2 antagonist 1 is a high-affinity and long-residence-time *CCR2* antagonist, with a K_i of 2.4 nM .

HY-14882R

Cenicriviroc (Standard) TAK-652 (Standard); TBR-652 (Standard)	CCR HIV Reference Standards	Infection Endocrinology
Cenicriviroc (Standard) is the analytical standard of Cenicriviroc. This product is intended for research and analytical applications. Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity .

HY-15450

INCB 3284 dimesylate	CCR	Endocrinology
INCB 3284 dimesylate is a potent, selective and orally bioavailable human *CCR2* antagonist, inhibiting monocyte chemoattractant protein-1 binding to *hCCR2, with an IC₅₀* of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

HY-50084

CCR2-RA	CCR	Cancer
CCR2-RA is a allosteric antagonist of chemokine (C-C motif) receptor 2 (CCR 2), and it can be used in cancer research .

HY-177596A

Dicytidine 5′-triphosphate trisodium Cp3C trisodium	CCR	Others
Dicytidine 5′-triphosphate (Cp3C) trisodium is a cytosine-containing dinucleoside polyphosphate. Dicytidine 5′-triphosphate trisodium inhibits the intracellular accumulation of trans-resveratrol and trans-piceid. Dicytidine 5′-triphosphate trisodium induces the expression of *CCR2* and upregulates the expression of PAL1 and 4CL1 .

Cat. No.	Product Name	Target	Research Area

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective *CCR2* inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective *CCR2* inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553B

DOTA-ECL1i	Radionuclide-Drug Conjugates (RDCs) CCR	Cardiovascular Disease Inflammation/Immunology Cancer
DOTA-ECL1i is a conjugate of the *CCR2* inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99781

Plozalizumab MLN-1202	CCR	Inflammation/Immunology Cancer
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) ^[2] .

HY-P991745

*Anti-Mouse CCR2* Antibody (C2Mab-6)**	CCR	Inflammation/Immunology
Anti-Mouse CCR2 Antibody (C2Mab-6) is raised against and binds to the N-terminal sequence of *CCR2*. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979) .

HY-P992120

Minokitug	CCR	Inflammation/Immunology
Minokitug is a humanized monoclonal antibody targeting the *CCR2* protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8501

Emestrin	Structural Classification Natural Products Microorganisms Source Classification	Bacterial
Emestrin is a mycotoxin originally isolated from E. striata that has antimicrobial, immunomodulatory, and cytotoxic activities. It is active against the fungi C. albicans and C. neoformans, as well as the bacteria E. coli, S. aureus, and methicillin-resistant S. aureus (MRSA; IC₅₀s=3.94, 0.6, 2.21, 4.55, and 2.21 μg/mL, respectively).2 Emestrin is a chemokine (C-C motif) receptor 2 (CCR2) antagonist (IC₅₀=5.4 μM in a radioligand binding assay using isolated human monocytes).3 Emestrin (0.1 μg/mL) induces apoptosis in HL-60 cells. It induces heart, thymus, and liver tissue necrosis in mice when administered at doses ranging from 18 to 30 mg/kg.

Species:	Human (2) Mouse (1)
Tag:	His (1) Tag Free (2) Myc (1)
Source:	HEK293 (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P77589

	CCR2b Protein-VLP, Human (HEK293) C-C CKR-2; ccr-2; ccr2; MCP-1-R; CMKBR2; ccr2	Human	HEK293
	CCR2b Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.

HY-P77590

	CCR2b Protein-VLP, Human (Biotinylated, HEK293) C-C CKR-2; ccr-2; ccr2; MCP-1-R; CMKBR2; ccr2	Human	HEK293
	CCR2b Protein-VLP, Human (Biotinylated, HEK293) is recommended only for SPR analysis. HY-P77589 can be used in animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.

HY-P700541

	CCR2 Protein, Mouse (N-His, C-Myc) 1 Publications Verification ccr2; chemokine (C-C motif) receptor 2; CMKBR2; CC CKR 2; CD192; CKR2; FLJ78302; MCP 1 R; ccr2A; ccr2B; CKR2A; CKR2B; MCP-1-R; CC-CKR-2	Mouse	E. coli
	CCR2 protein is an important chemokine receptor that coordinates chemotaxis and migration by binding to CCL2, CCL7, and CCL12 and activating the PI3K cascade. In addition to chemokine signaling, CCR2 regulates T cell inflammatory cytokines, promotes Th17 cell generation, and promotes mature thymocyte output. CCR2 Protein, Mouse (N-His, C-Myc) is the recombinant mouse-derived CCR2 protein, expressed by E. coli , with C-Myc, N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2) Rabbit (2)
Reactivity:	Human (4) Mouse (1)
Application:	IHC-P (2) IF-Tissue (1) IP (2) IHC-F (1) WB (3) FC (4) ELISA (2)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (4) Biotin (1)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84311

	CCR2 Antibody (YA4008) ccr2; CKR2; ccr-2; ccr2A; ccr2B; CKR2A; CKR2B; CMKBR2; MCP-1-R; CC-CKR-2	WB, FC, ELISA	Human
	CCR2 Antibody (YA4008) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CCR2.

HY-P84311A

	CCR2 Antibody (YA4008)(PBS only) ccr2; CKR2; ccr-2; ccr2A; ccr2B; CKR2A; CKR2B; CMKBR2; MCP-1-R; CC-CKR-2	WB, FC, ELISA	Human
	CCR2 Antibody (YA4008) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CCR2.

HY-P87536

	CCR-2 Antibody (YA7220)	IHC-P, IHC-F, IF-Tissue, FC, IP	Human
	CCR-2 Antibody (YA7220) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CCR-2.

HY-P80385

	CCR2 Antibody (YA548) 1 Publications Verification C C chemokine receptor type 2 antibody; C C CKR 2 antibody; C-C chemokine receptor type 2 antibody; C-C CKR-2 antibody; CC chemokine receptor type 2 antibody; CC CKR 2 antibody; CC-CKR-2 antibody; CCCKR2 antibody; ccr 2 antibody; ccr-2 antibody; ccr1L antibody; ccr2 antibody; ccr2_HUMAN antibody; ccr2A antibody; ccr2B antibody; ccr5L antibody; CD192 antibody; CD192 antigen antibody; Chemokine C C motif receptor 2 antibody; Chemokine CC Motif Receptor 2 antibody; CKR 2 antibody; CKR2 antibody; CKR2A antibody; CKR2B antibody; CMKBR2 antibody; MCP 1 R antibody; MCP-1-R antibody; MCP1 RECEPTOR antibody; MCP1R antibody; Monocyte chemoattractant protein 1 receptor antibody; Monocyte Chemotactic Protein 1 Receptor antibody; Monocyte Chemotactic Protein 1 Receptor antibody	WB, IHC-P, IP, FC	Human, Mouse
	CCR2 Antibody (YA548) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CCR2.